Express Pharma
MARCH 31, 2025
This is different from traditional chemotherapy which is usually given orally and intravenously. It was launched in 2004 with a $22 million endowment from Mark and Mary Stevens. Researchers completed phase 1 clinical trials demonstrating safety and tolerance to NEO100 in 2019.
Pharmacy Times
JUNE 10, 2025
December 21, 2004. PR Newswire. June 10, 2025. Accessed June 10, 2025. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Thyroid Pharmacist
NOVEMBER 4, 2022
A study in 2004 found that there is an association between the presence of an anxiety or mood disorder, and the presence of TPO antibodies. (33) Selenium may also interact with other supplements and medications, such as cholesterol-lowering statin drugs, antacids, chemotherapy drugs, corticosteroids, niacin, and even birth control pills.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.
pharmaphorum
JANUARY 19, 2022
EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. But prevalence still increased by 10% between 2008 and 2012.
The Thyroid Pharmacist
JULY 8, 2022
Interestingly, a 2004 study found an association between the presence of an anxiety or mood disorder, and the presence of thyroid peroxidase (TPO) antibodies. (4). Published 2004 Aug 18. 2004 Jun;18(2):303-16. I remember my own disbelief when, after taking selenium supplements, my frequent panic attacks completely disappeared!
European Pharmaceutical Review
JULY 26, 2022
The committee has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy.
Expert insights. Personalized for you.
Let's personalize your content